Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News KaloBios Pharmaceuticals, Inc. KBIO

Healthcare Biotechnology
"KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company focuses on developing medicines for patients with neglected and rare diseases through innovative and responsible business models."

Recent & Breaking News (OTCPK:KBIO)

KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia

PR Newswire July 29, 2015

KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement

PR Newswire July 29, 2015

KaloBios Announces Shareholders and Board of Directors Approval of Reverse Stock Split

PR Newswire July 13, 2015

KaloBios to Present at the JMP Securities Life Sciences Conference

PR Newswire June 17, 2015

KaloBios Appoints Ronald A. Martell Executive Chairman

PR Newswire May 28, 2015

KaloBios Reports First Quarter 2015 Financial Results

PR Newswire May 11, 2015

KaloBios Elects Ronald A. Martell to Board of Directors

PR Newswire April 22, 2015

KaloBios to Present at the 14th Annual Needham Healthcare Conference

PR Newswire April 6, 2015

KaloBios Reports Fourth Quarter 2014 Financial Results

PR Newswire March 16, 2015

KaloBios Announces Upcoming Investor Conference Participation

PR Newswire February 3, 2015

KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer

PR Newswire January 8, 2015

KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients

PR Newswire January 6, 2015

KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors

PR Newswire December 1, 2014

KaloBios Announces Upcoming Scientific and Investor Conference Participation

PR Newswire November 11, 2014

KaloBios Reports Third Quarter Financial Results

PR Newswire November 6, 2014

Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy

PR Newswire August 14, 2014

KaloBios Provides Clinical Update and Reports Second Quarter Financial Results

PR Newswire August 7, 2014

KaloBios Provides Update on KB001-A Partnership and Clinical Status

PR Newswire July 28, 2014

KaloBios to Present at 9th Annual JMP Securities Healthcare Conference

PR Newswire June 11, 2014

KaloBios to Present at Jefferies 2014 Global Healthcare and BBC Boston CEO Conferences

PR Newswire May 21, 2014